As a matter of fact, this miRNA has been suggested as a therapeutic target to manage both NAFLD and Mets, given that it is deeply involved in both cholesterol and FAs metabolism, by targeting key enzymes in cholesterol synthesis pathway (i.e., ABCA1 and ABCG1, CPT1A and AMPKα), and in glucose metabolism, by inhibiting gluconeogenesis through the modulation of phosphoenolpyruvate carboxykinase (PCK1) and glucose-6-phosphatase (G6PC) [151,152,153,154,155]. This evidence concerns the gene G6PC1 and metabolic dysfunction-associated steatotic liver disease.